Clinical Trials Logo

Recurrent Salivary Gland Cancer clinical trials

View clinical trials related to Recurrent Salivary Gland Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01332279 Withdrawn - Tongue Cancer Clinical Trials

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Start date: April 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of giving everolimus (RAD001) and erlotinib hydrochloride together with radiation therapy in treating patients with recurrent head and neck cancer previously treated with radiation therapy. RAD001 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving RAD001 and erlotinib hydrochloride together with radiation therapy may kill more tumor cells.